WO1998056357A1 - Formulation a liberation prolongee pour medicaments de base faiblement solubles - Google Patents

Formulation a liberation prolongee pour medicaments de base faiblement solubles Download PDF

Info

Publication number
WO1998056357A1
WO1998056357A1 PCT/US1997/010705 US9710705W WO9856357A1 WO 1998056357 A1 WO1998056357 A1 WO 1998056357A1 US 9710705 W US9710705 W US 9710705W WO 9856357 A1 WO9856357 A1 WO 9856357A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
alginate
sodium
acid
salt
Prior art date
Application number
PCT/US1997/010705
Other languages
English (en)
Inventor
Neville W. Broad
Alan F. Carmody
Liam C. Feely
Brian C. Withers
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/574,877 external-priority patent/US5705190A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to SK1612-99A priority Critical patent/SK282427B6/sk
Priority to PCT/US1997/010705 priority patent/WO1998056357A1/fr
Priority to SI9720096A priority patent/SI20108B/sl
Publication of WO1998056357A1 publication Critical patent/WO1998056357A1/fr
Priority to NO996161A priority patent/NO310095B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

Cette invention se rapporte à une composition pharmaceutique solide, à libération prolongée, pour administration orale, adaptée à une posologie quotidienne réduite, dont l'ingrédient thérapeutique est un médicament de base faiblement soluble. Ladite formulation comporte un mélange d'un alginate soluble dans l'eau, d'un sel complexe de l'acide alginique et d'un acide carboxylique organique avec le médicament thérapeutique. Une réalisation particulière de cette invention concerne une forme posologique à administrer une fois par jour, dont l'ingrédient thérapeutique est constitué de clarithromycine.
PCT/US1997/010705 1995-12-19 1997-06-11 Formulation a liberation prolongee pour medicaments de base faiblement solubles WO1998056357A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SK1612-99A SK282427B6 (sk) 1997-06-11 1997-06-11 Pevná farmaceutická kompozícia s riadeným uvoľňovaním
PCT/US1997/010705 WO1998056357A1 (fr) 1995-12-19 1997-06-11 Formulation a liberation prolongee pour medicaments de base faiblement solubles
SI9720096A SI20108B (en) 1997-06-11 1997-06-11 A controlled release formulation for poorly soluble basic drugs
NO996161A NO310095B1 (no) 1997-06-11 1999-12-13 En kontrollert frigjørende formulering for tungt løselige basiske legemidler

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/574,877 US5705190A (en) 1995-12-19 1995-12-19 Controlled release formulation for poorly soluble basic drugs
PCT/US1997/010705 WO1998056357A1 (fr) 1995-12-19 1997-06-11 Formulation a liberation prolongee pour medicaments de base faiblement solubles

Publications (1)

Publication Number Publication Date
WO1998056357A1 true WO1998056357A1 (fr) 1998-12-17

Family

ID=22261117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/010705 WO1998056357A1 (fr) 1995-12-19 1997-06-11 Formulation a liberation prolongee pour medicaments de base faiblement solubles

Country Status (4)

Country Link
NO (1) NO310095B1 (fr)
SI (1) SI20108B (fr)
SK (1) SK282427B6 (fr)
WO (1) WO1998056357A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066174A2 (fr) * 1999-04-29 2000-11-09 Russinsky Limited Composes
EP1118333A1 (fr) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions avec une biodisponibilité orale augmentée
WO2003082248A2 (fr) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Compositions a gout masque d'erythromycine a et derives de ces compositions
WO2004032904A1 (fr) * 2002-10-08 2004-04-22 Krka, Tovarna Zdravil, D.D. Compositions pharmaceutiques contenant des alginates
CN100336511C (zh) * 2002-11-15 2007-09-12 江苏豪森药业股份有限公司 口服罗红霉素控释制剂
CN100341886C (zh) * 2000-11-27 2007-10-10 桑多斯股份公司 大环内酯类化合物的溶剂化物
EP2535042A1 (fr) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Composition à libération prolongée orale comprenant a macrolide
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
US11433083B2 (en) 2010-11-30 2022-09-06 Lipocine Inc. High-strength testosterone undecanoate compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11707467B2 (en) 2014-08-28 2023-07-25 Lipocine Inc. (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
EP0188040A1 (fr) * 1985-01-11 1986-07-23 Abbott Laboratories Limited Préparation solide à libération lente
WO1997022335A1 (fr) * 1995-12-19 1997-06-26 Abbott Laboratories Formulation a liberation controlee pour medicaments basiques peu solubles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163823A (ja) * 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
EP0188040A1 (fr) * 1985-01-11 1986-07-23 Abbott Laboratories Limited Préparation solide à libération lente
WO1997022335A1 (fr) * 1995-12-19 1997-06-26 Abbott Laboratories Formulation a liberation controlee pour medicaments basiques peu solubles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 8540, Derwent World Patents Index; AN 85-247033 [40], XP002028797 *

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066174A2 (fr) * 1999-04-29 2000-11-09 Russinsky Limited Composes
WO2000066174A3 (fr) * 1999-04-29 2001-03-15 Russinsky Ltd Composes
EP1118333A1 (fr) * 2000-01-18 2001-07-25 Eurand International S.P.A. Compositions avec une biodisponibilité orale augmentée
CN100341886C (zh) * 2000-11-27 2007-10-10 桑多斯股份公司 大环内酯类化合物的溶剂化物
WO2003082248A2 (fr) * 2002-04-03 2003-10-09 Ranbaxy Laboratories Limited Compositions a gout masque d'erythromycine a et derives de ces compositions
WO2003082248A3 (fr) * 2002-04-03 2003-12-24 Ranbaxy Lab Ltd Compositions a gout masque d'erythromycine a et derives de ces compositions
EA007488B1 (ru) * 2002-10-08 2006-10-27 Крка, Товарна Здравил, Д. Д. Ново Место Фармацевтические композиции с контролируемым высвобождением, содержащие альгинат натрия и альгинат натрия-кальция
WO2004032904A1 (fr) * 2002-10-08 2004-04-22 Krka, Tovarna Zdravil, D.D. Compositions pharmaceutiques contenant des alginates
HRP20050312B1 (hr) * 2002-10-08 2014-09-26 Krka, Tovarna Zdravil, D.D. Farmaceutski pripravci s kontroliranim oslobađanjem koji sadržavaju natrijev alginat i natrij kalcij alginat
CN100336511C (zh) * 2002-11-15 2007-09-12 江苏豪森药业股份有限公司 口服罗红霉素控释制剂
EP2535042A1 (fr) * 2003-06-16 2012-12-19 ANDRX Pharmaceuticals LLC. Composition à libération prolongée orale comprenant a macrolide
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US11052096B2 (en) 2009-01-08 2021-07-06 Lipocine Inc. Steroidal compositions
US9943527B2 (en) 2010-11-30 2018-04-17 Lipocine Inc. High-strength testosterone undecanoate compositions
US10973833B2 (en) 2010-11-30 2021-04-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US9757390B2 (en) 2010-11-30 2017-09-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US11433083B2 (en) 2010-11-30 2022-09-06 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9949985B2 (en) 2010-11-30 2018-04-24 Lipocine Inc. High-strength testosterone undecanoate compositions
US10226473B2 (en) 2010-11-30 2019-03-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US11364250B2 (en) 2010-11-30 2022-06-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US10716794B2 (en) 2010-11-30 2020-07-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US10799513B2 (en) 2010-11-30 2020-10-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US10881671B2 (en) 2010-11-30 2021-01-05 Lipocine Inc. High-strength testosterone undecanoate compositions
US11364249B2 (en) 2010-11-30 2022-06-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US11311555B2 (en) 2010-11-30 2022-04-26 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
US11298365B2 (en) 2014-08-28 2022-04-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US9757389B2 (en) 2014-08-28 2017-09-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US11707467B2 (en) 2014-08-28 2023-07-25 Lipocine Inc. (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use
US11872235B1 (en) 2014-08-28 2024-01-16 Lipocine Inc. Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy

Also Published As

Publication number Publication date
SI20108B (en) 2001-12-31
NO996161L (no) 1999-12-13
NO996161D0 (no) 1999-12-13
NO310095B1 (no) 2001-05-21
SK282427B6 (sk) 2002-01-07
SI20108A (sl) 2000-06-30
SK161299A3 (en) 2000-05-16

Similar Documents

Publication Publication Date Title
EP0799028B1 (fr) Formulation a liberation controlee pour medicaments basiques peu solubles
US5415871A (en) Therapeutic agents
CA2529746C (fr) Composition orale a liberation prolongee
WO1998056357A1 (fr) Formulation a liberation prolongee pour medicaments de base faiblement solubles
Davey The pharmacokinetics of clarithromycin and its 14-OH metabolite
US5213806A (en) Pharmaceutical composition comprising calcium polycarbophil
CZ314899A3 (cs) Farmaceutický prostředek
WO2003105810A1 (fr) Compositions pharmaceutiques pour medicaments ayant une solubilite dependant du ph
JPS6241646B2 (fr)
US8124123B2 (en) Controlled release azithromycin solid dosages forms
CN1843505A (zh) 复方多西环素溶菌酶肠溶胶囊
US20060099266A1 (en) Slow release formulation of clarithromycin
TW202143959A (zh) 一種非布司他片
MXPA97006031A (en) A controlled release formulation for basic pharmacy deficiently solub
HRP970325A2 (en) Controlled release formulation for poorly soluble basic drugs
JPH1081634A (ja) 溶解時間を制御した基剤
US20050260263A1 (en) Sustained release formulation for sparingly soluble main drugs
BG65116B1 (bg) Лекарствена форма с контролирано освобождаване наслабо разтворими основни лекарствени средства
CN100435847C (zh) 含有难溶解性主药之持续释放配方
KR20240040407A (ko) 사쿠비트릴ㆍ발사르탄 칼슘염을 포함하는 약제학적 조성물
TW200536570A (en) Controlled-release formulation containing active pharmaceutical ingredient with poor solubility

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): BG NO SI SK

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 161299

Country of ref document: SK